ClinicalTrials.gg
RecruitingNCT07407738IVLUpdated Sep 29, 2026

ShockFast Intravascular Lithotripsy Device for Treatment of Calcified Coronary Lesions

An interventional study of Shockwave IVL and Shockfast IVL in Coronary Arterial Disease and Calcified Coronary Artery Disease, sponsored by Shunmei Medical. Recruiting at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Shunmei Medical · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Sep 29, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 154 studies in Coronary Artery Disease with a site in Poland — 33 open to participants now, 47 under way, 4 of them phase 3. Coronary Artery Disease · Poland.

Planned enrollment
85th of 114
120 · median 348
Started
2026
with 4 others
No phase
64 of 154
17 open now
Primary completion
2026-11
later than 21 of 46 live
Registered
152nd of 154
by date

Among the 154 studies in Coronary Artery Disease with a site in Poland, this one is the 85th largest by planned enrollment of the 114 interventional ones that give a count, is one of 5 that started in 2026, is one of 64 with no phase, reaches primary completion later than 21 of the 46 other live ones, and was the 152nd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

33 of the 154 studies in Coronary Artery Disease with a site in Poland are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 154 studies in Coronary Artery Disease with a site in Poland, or all of them as a file.
02

Study summary

Coronary artery disease is caused by narrowing of the artery lumen. Treatment with Percutaneous Coronary Intervention (PCI) may be needed. This is a minimally invasive procedure used to treat narrowed or blocked coronary arteries. Sometimes a stent is placed to keep the artery open. If the lesions in the coronary artery are calcified, this may cause difficulties for successful stent placement. The calcified plaques can be fractured via intravascular lithotripsy (IVL) with devices like ShockWave IVL and ShockFast IVL. The aim of this study is to compare the this relatively new ShockFast IVl with the more widely used ShockWave IVL.

Read the detailed description

Coronary calcified lesions have evolved as one of the most challenging indications for coronary percutaneous interventions (PCI). Different dedicated devices have been recently introduced into the market to improve procedural success in this challenging PCI population. Shockwave Intravascular Lithotripsy, (Shockwave IVL), Shockwave Medical, SC, CA, USA, was the first intracoronary device that used sonic pressure to fracture intracoronary calcium. The device safety and efficacy has been proved in a series of clinical trials. ShockFast intravascular lithotripsy (ShockFast IVL), Shunmei medical, Shenzhen, China, is a new dedicated device to treat intracoronary calcium that makes use of sonic pressure waves to fracture calcified plaques. ShockFast IVL has recently obtained CE mark approval for this indication.

The aim of this study is to compare this new lithotripsy device (ShockFast IVL) with the existing and widely used lithotripsy device that uses the same principle of action, the Shockwave IVL, Shockwave Medical, SC, CA, USA.

03

Conditions studied

  • Coronary Arterial Disease
  • Calcified Coronary Artery Disease

Keywords

  • Shockwave Intravascular Lithotripsy
  • Shockfast Intravascular Lithotripsy
  • Coronary Calcified Lesion
  • IVL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥18 years undergoing PCI for stable or unstable angina or staged procedure after successful treatment of a myocardial infarction where heart enzymes are decreasing

    Angiographic criteria:

  2. Native de novo coronary lesions
  3. Vessel diameter between 2.5mm - 4.0mm
  4. Lesion Length: ≤40mm
  5. Severe Calcification:

    1. Calcification visible on the upper and the lower sides of the vessel wall in at least two angiographic projections that differ ≥ 60° from each other
    2. Presence of severe calcified protruding noduli
  6. No flow disturbances at baseline (Thrombolysis in Myocardial Infarction [TIMI] 3 flow at baseline)
  7. Target lesion with diameter stenosis ≥70% by visual, or ≥50% with evidence of clinical ischemia

    OCT Criteria:

  8. Total calcium arc > 180° or
  9. Presence of a protruding calcified noduli

Exclusion criteria

Exclusion Criteria:

  1. less than 25%
  2. Lesion located in Left Main (LM) coronary artery
  3. Calcifications located mostly > 0.5 mm from the vessel lumen.
  4. Severe renal Impairment; Serum Creatinine > 220 μmol or currently undergoing hemodialysis
  5. Severe lesion tortuosity where OCT is judged impossible to cross.
  6. Inability to tolerate dual antiplatelet therapy for 6 months or longer
  7. Inability to obtain inform consent or deemed poorly compliant by the investigator
  8. Presence of permanent pacemaker
  9. Angiographic evidence of thrombus in the target vessel
  10. Target lesion located at or involving within 5mm of the coronary ostium of the Left Anterior Descending artery (LAD), Left Circumflex artery (LCX)
  11. Target lesion is a chronic total occlusion (CTO)
  12. Presence of aneurysm within 10mm proximal or distal to the target lesion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Shockfast IVL

    Interventional procedure using a dedicated device to treat coronary calcified lesions by offering precise control of sonic pressure waves for safe fracture calcium deposits within the artery walls, thus maintaining vessel flexibility and promoting smoother stent placement. The ShockFast device has an improved crossing profile and 2 lengths of the catheter: 12 and also 15mm compared to ShockWave which has only 1 length.

    Device: Shockfast IVL

  • Active comparator
    Shockwave IVL

    Interventional procedure that utilizes a fluid-filled catheter connected to an energy source that generates mechanistically tuned ultrasonic acoustic pressure waves - or Shockwaves - for modification, fracture, and fragmentation of vascular calcification.

    Device: Shockwave IVL

Interventions

  • DeviceShockwave IVL

    Treatment of subjects with coronary calcified lesions with an interventional procedure that utilizes a fluid-filled catheter connected to an energy source that generates mechanistically tuned ultrasonic acoustic pressure waves - or Shockwaves - for modification, fracture, and fragmentation of vascular calcification.

  • DeviceShockfast IVL

    Treatment of subjects with coronary calcified lesions with an interventional procedure using a dedicated device to treat coronary calcified lesions by offering precise control of sonic pressure waves for safe fracture calcium deposits within the artery walls, thus maintaining vessel flexibility and promoting smoother stent placement. The ShockFast device has an improved crossing profile and 2 lengths of the catheter: 12 and also 15mm compared to ShockWave which has only 1 length.

06

What researchers measure

Primary outcomes

  1. Stent area post PCI measured at the minimal lumen area during initial procedure, evaluated by OCT

    Time frame: Hospitalisation (during procedure)

Secondary outcomes

  1. Target lesion failure defined as cardiac death, target-vessel myocardial infarction and target-lesion revascularisation at discharge and 30 days

    Time frame: 30 day follow-up

  2. Angiographic success

    * Defined as a successful stent delivery with diameter of stenosis post PCI of \<50% without severe dissection (type D-F), perforation, abrupt vessel closure or persistent less than Thrombolysis in Myocardial Infarction (TIMI)-3 flow. * By collecting data through angiography and imaging: * Minimal lumen area post stenting * Residual area of stenosis * Residual diameter of stenosis \<30% * Residual diameter of stenosis \<50% * Optical Coherence Tomography (OCT) measured under expansion (\<80% of the reference lumen area) * Post-IVL acute area gain (measured at the minimum lumen area post IVL) * Number of visible calcium cracks post IVL * Severe coronary dissection post IVL (type C-F)

    Time frame: Hospitalisation (during procedure)

  3. Device success

    Defined as success of the device to cross and fully expand

    Time frame: Hospitalisation (during procedure)

07

Study locations

9 of 13 sites recruiting
  • Infirmerie Protestante de Lyon
    Lyon, France
    Recruiting
    • Dr. Faurie · Principal investigator
  • Centre Cardiologique du Nord
    Paris, France
    Recruiting
    • Dr. Digne · Principal investigator
  • Centre Hospitalier de Valenciennes
    Valenciennes, France
    Withdrawn

    Not enrolling at this site.

  • Segeberger Kliniken GMBH / Herz- und Gefäßzentrum
    Bad Segeberg, Germany
    Recruiting
    • Holger Prof. Nef · Contact
    • Prof. Nef · Principal investigator
  • MediClin Heart Center Lahr
    Lahr, Germany
    Not yet recruiting
    • Kambis Prof. Mashayekhi · Contact
    • Prof. Mashayekhi · Principal investigator
  • Medical University of Silesia
    Katowice, Poland
    Not yet recruiting
    • Prof. Wojakowski · Principal investigator
  • University Hospital Krakow
    Krakow, Poland
    Not yet recruiting
    • Prof. Bartus · Principal investigator
  • Miedziowe Centrum Zdrowia
    Lubin, Poland
    Recruiting
    • Dr. Wlodarczak · Principal investigator
  • Regional Specialist Hospital
    Wroclaw, Poland
    Recruiting
    • Prof. Roleder · Principal investigator
  • La Paz University Hospital
    Madrid, Spain
    Recruiting
    • Dr. Moreno · Principal investigator
  • La Princesa Univeristy Hospital
    Madrid, Spain
    Recruiting
    • Dr. Alfonso · Principal investigator
  • Virgen Arrixaca University Clinical Hospital
    Murcia, Spain
    Recruiting
    • Dr. Pinar · Principal investigator
  • Virgen del Rocío University Hospital
    Seville, Spain
    Recruiting
    • Dr. Diaz · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 8 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 12, 2026
StartActual
Feb 16, 2026
Primary completionEst.
Nov 1, 2026
CompletionEst.
Mar 1, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (2 now recruiting, 1 now withdrawn)
Show 3 sites
  • Segeberger Kliniken GMBH / Herz- und Gefäßzentrum · Bad Segeberg, GermanyNot yet recruiting→Recruiting
  • La Princesa Univeristy Hospital · Madrid, SpainActive, not recruiting→Recruiting
  • Centre Hospitalier de Valenciennes · Valenciennes, FranceNot yet recruiting→Withdrawn
across 2 updates, Sep 25, 2026 – Sep 29, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Segeberger Kliniken GMBH / Herz- und Gefäßzentrum · Bad Segeberg, GermanyContact added (no phone or email listed)Contact added (no phone or email listed)
  • La Princesa Univeristy Hospital · Madrid, SpainContact added (no phone or email listed)
  • Centre Hospitalier de Valenciennes · Valenciennes, FranceContact removed (no phone or email listed)
across 2 updates, Sep 25, 2026 – Sep 29, 2026
Show all 2 updates
  1. Sep 29, 2026
    2 sites changed recruiting status (1 now withdrawn, 1 now recruiting)
    Show 2 sites
    • Centre Hospitalier de Valenciennes · Valenciennes, FranceNot yet recruiting→Withdrawn
    • Segeberger Kliniken GMBH / Herz- und Gefäßzentrum · Bad Segeberg, GermanyActive, not recruiting→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Centre Hospitalier de Valenciennes · Valenciennes, FranceContact removed (no phone or email listed)
    • Segeberger Kliniken GMBH / Herz- und Gefäßzentrum · Bad Segeberg, GermanyContact added (no phone or email listed)Contact added (no phone or email listed)
  2. Sep 25, 2026
    2 sites changed recruiting status (1 now active, not recruiting, 1 now recruiting)
    Show 2 sites
    • Segeberger Kliniken GMBH / Herz- und Gefäßzentrum · Bad Segeberg, GermanyNot yet recruiting→Active, not recruiting
    • La Princesa Univeristy Hospital · Madrid, SpainActive, not recruiting→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Segeberger Kliniken GMBH / Herz- und Gefäßzentrum · Bad Segeberg, GermanyContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • La Princesa Univeristy Hospital · Madrid, SpainContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07407738
Lead sponsor
Shunmei Medical
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Feb 16, 2026
Primary completion
Nov 1, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Jasper Yang
Contact
cm@shunmed.com
008615363476127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion